Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Indivior PLC (NASDAQ: INDV) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a pharmaceutical issuer focused on opioid use disorder (OUD) treatments, Indivior uses its filings to report financial results, strategic initiatives, governance changes, and key legal and regulatory matters.
Investors can review Form 8-K current reports in which Indivior details material events such as quarterly financial results, updates on the Indivior Action Agenda, restructuring charges, optimization of its Rest of World business, and changes to executive compensation or board composition. Other 8-K items describe the company’s intent to redomicile from the U.K. to Delaware, shareholder approvals of a scheme of arrangement and amended articles of association, and the conclusion of a legacy U.S. Department of Justice resolution agreement.
Through its periodic reports (Forms 10-K and 10-Q, when available on EDGAR), readers can examine segment performance, revenue composition, R&D spending, and risk factors related to Indivior’s OUD-focused portfolio, including SUBLOCADE, SUBOXONE Film, PERSERIS, and OPVEE. These filings also typically include detailed discussions of non-GAAP measures such as adjusted EBITDA and non-GAAP operating expenses, along with reconciliations to U.S. GAAP metrics.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important points in lengthy filings, helping users quickly understand changes in guidance, restructuring actions, legal exposures, or capital structure. Real-time updates from EDGAR mean that new Indivior filings, including any future proxy statements on executive compensation and Form 4 insider transaction reports, are surfaced promptly.
By using this page, investors, analysts, and other stakeholders can efficiently navigate Indivior’s SEC reporting history, monitor developments in its OUD pharmaceutical business, and interpret the financial and governance implications of its regulatory disclosures.
Indivior Pharmaceuticals, Inc. is asking shareholders to vote at its 2026 virtual annual meeting on May 13, 2026, on four items: electing eight directors, approving executive pay on an advisory basis, choosing annual say‑on‑pay frequency, and ratifying PwC as auditor.
Management highlights 2025 as a strong transition year. Total net revenue rose 4% to $1.24 billion, driven by SUBLOCADE, whose net revenue grew 13% to a record $856 million. GAAP net income reached $210 million, and adjusted EBITDA increased 20% to $428 million with a 35% margin.
The company completed Phase I of its Indivior Action Agenda, simplified its operating model, and ended 2025 with net leverage of 0.7x. It resolved a legacy DOJ matter and authorized a $400 million share repurchase program, while re‑domiciling from the U.K. to Delaware and aligning governance and compensation with U.S. practices.
Indivior Pharmaceuticals Schedule 13G: Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 4,806,556 shares of Common Stock, representing 3.8% of the class. The filing states that after acquiring beneficial ownership of more than 5% on March 17, 2026, the reporting persons ceased to be beneficial owners of more than 5% by the date of this filing.
The reported shares are held by entities subject to voting and investment discretion by Millennium Management LLC and related managers. A Joint Filing Agreement dated March 20, 2026 is attached and signatures are provided by the reporting persons.
Indivior Pharmaceuticals, Inc. Chief Financial Officer Ryan Preblick reported routine equity compensation activity. On March 14, 2026, 6,302 restricted stock units vested and converted into the same number of common shares. To cover tax withholding obligations, 2,843 of these shares were withheld at $31.11 per share, leaving a net increase of 3,459 shares. Following these transactions, Preblick directly holds 320,751 shares of Indivior common stock.
Indivior Pharmaceuticals, Inc. issued $500,000,000 of 0.625% Convertible Senior Notes due 2031. The Notes bear 0.625% interest, payable semi-annually, and mature on March 15, 2031, unless earlier repurchased, redeemed or converted.
Before December 16, 2030, holders may convert only upon certain events; afterward they may convert at any time until shortly before maturity. The company may settle conversions in cash and, if applicable, common stock. The initial conversion rate is 24.0033 shares per $1,000 principal amount, with customary anti-dilution adjustments and potential “make-whole” increases after specified corporate events.
The Notes are senior, unsecured obligations with standard events of default and conditional redemption and fundamental change repurchase features. A portion of the proceeds was used to prepay all outstanding principal, interest and fees under a prior Note Purchase Agreement, which was terminated on March 17, 2026. Initially, up to 16,202,200 shares of common stock may be issuable upon conversion based on an initial maximum conversion rate of 32.4044 shares per $1,000 principal amount.
Indivior Pharmaceuticals director Barbara Ryan reported an open-market purchase of common stock. Ryan bought 8 shares at $31.085 per share on March 13, 2026. Following this trade, Ryan directly holds 5,724 shares of Indivior Pharmaceuticals common stock.
Indivior Pharmaceuticals, Inc. reported that it has priced an offering of 0.625% convertible senior notes due 2031. These notes are a form of debt that can be converted into shares of Indivior’s common stock under specified conditions.
The company furnished a press release dated March 12, 2026 as Exhibit 99.1, providing additional details on the note offering. The filing clarifies that neither this report nor the press release is an offer to sell or a solicitation to buy the notes or any related common stock.
Indivior Pharmaceuticals, Inc. plans a private offering of $400,000,000 of convertible senior notes due March 15, 2031, with an option for initial purchasers to buy up to an additional $60,000,000.
The senior unsecured notes will pay semi-annual interest and may be converted in certain situations into cash and, if applicable, common stock. Indivior expects to use about $239 million of net proceeds plus about $102 million of cash on hand to repay and terminate its term loan and revolving credit facility, to use up to approximately $75 million to repurchase common shares from certain note purchasers at the notes’ pricing, and to apply the remainder to general corporate purposes.
Indivior Pharmaceuticals, Inc. director Stuart A. Kingsley bought additional shares of the company in the open market. On March 6, 2026, he purchased 940 shares of Common Stock at an average price of $31.865 per share. Following this open‑market purchase, he directly owns 5,582 shares of Indivior common stock.
Indivior Pharmaceuticals, Inc. director Ryan Barbara reported an open-market purchase of common stock. On March 9, 2026, Ryan Barbara bought 31 shares of Indivior common stock at $32.56 per share. After this trade, the director directly owns 5,716 shares of Indivior common stock.